ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries.
 PMID: 35061671       2022       PloS one
Result: The most prevalent PI DRMs were M46I (3/120; 2.5%) and L10F (2/120; 1.7%) in Armenia and N88D (2/96; 2.1%) in Azerbaijan.
Discussion: The most frequent PI DRMs included M46I and L90M, which are associated with DR to nelfinavir, which was not considered for PDR estimation and has not been used since 2013; additionally, N88D and L10F only minimally reduce susceptibility to drugs.


  Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia.
 PMID: 34622550       2022       HIV medicine
Abstract: Most common mutations were M184V (57.1%), Y188C (25.7%), M46I/L (25.7%) and V82A/M (25.7%).


  Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
 PMID: 34694878       2022       Antimicrobial agents and chemotherapy
Table: M46I


  Diversity of HIV-1 Subtypes and Transmitted Drug-resistance Mutations Among Minority HIV-1 Variants in a Turkish Cohort.
 PMID: 34802406       2022       Current HIV research
Abstract: M41L, L74I, K65R, M184V, and M184I related to NRTI, K103N to NNRTI, and N83D, M46I, I84V, V82A, L24I, L90M, I54V to the PI sites were identified using NGS.


  Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.
 PMID: 34873084       2022       AIDS (London, England)
Table: M46I/L


  Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
 PMID: 34897227       2022       Journal of acquired immune deficiency syndromes (1999)
Table: M46I/L
Table: M46I


  Prevalence of transmitted drug resistance among ART-naive HIV-infected individuals, Beijing, 2015-2018.
 PMID: 35092830       2022       Journal of global antimicrobial resistance
Abstract: K103N/KN (NNRTI associated) and M46L/I/IMV/IM/ML (protease inhibitor associated) were the other major resistance mutations.


  Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.
 PMID: 35300056       2022       Pharmacogenomics and personalized medicine
Result: Additionally, the most common protease inhibitors associated mutation was Q58E (0.23%, 11/865), followed by M46I (4.05%, 5/865) and L33F (2.89%, 3/865)(as shown in Figure 2).


  High Level of Pre-Treatment HIV-1 Drug Resistance and Its Association with HLA Class I-Mediated Restriction in the Pumwani Sex Worker Cohort.
 PMID: 35215866       2022       Viruses
Result: The HLA-DRM associations involving HLA alleles at >10% frequency in Kenya are A*68:02 with DRMs G190ES (p = 0.008), IN E138K (p = 0.042), C*17:01 with DRMs M46I (p = 0.018), and IN E138K (p = 0.021).
Discussion: The clinically significant mutations with the highest prevalence among the study participants were M184I (37%) and E138AK (15%) on RT, D30N (10%) and M46I (8%) on PR, and E138K (6%) on IN.


  Trends of Transmitted and Acquired Drug Resistance in Europe From 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-late Presenters.
 PMID: 35495657       2022       Frontiers in microbiology
Abstract: The most prevalent TDR drug resistance mutations, in both LP and NLP, were K103N/S, T215rev, T215FY, M184I/V, M41I/L, M46I/L, and L90M.



Browser Board

 Co-occurred Entities




   Filtrator